Merck

$80.49
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.21 (+0.26%) As of 10:17 AM EST today

Why Robinhood?

You can buy or sell Merck and other stocks, options, and ETFs commission-free!

About MRK

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ. The listed name for MRK is Merck & Co., Inc.

CEO
Kenneth C. Frazier
Employees
71,000
Headquarters
Kenilworth, New Jersey
Founded
1891
Market Cap
204.17B
Price-Earnings Ratio
17.77
Dividend Yield
3.03
Average Volume
8.91M
High Today
$80.89
Low Today
$80.02
Open Price
$80.03
Volume
1.59M
52 Week High
$92.64
52 Week Low
$65.25

Collections

MRK News

Benzinga23h

Merck To Buy Late-Stage COVID-19 Treatment Company OncoImmune For $425M In Cash

Merck & Co., Inc. (NYSE: MRK), which has been lagging behind some of its large-pharma peers in COVID-19 treatment and vaccine development, announced the purchas
ReutersNov 23

US STOCKS-Wall St set to rise as vaccine progress fuels recovery hopes

* Vaccine could reach first Americans by mid-December * Surging coronavirus cases cap stock market gains * Merck rises on adding experimental COVID-19 therapy
CNBCNov 23

Stocks making the biggest moves in the premarket: Merck, Korn Ferry, Regeneron & more

Take a look at some of the biggest movers in the premarket: Merck (MRK) – Merck is buying privately-held drug maker OncoImmune for $425 million cash. OncoImmun

MRK Earnings

$0.00
$0.58
$1.16
$1.74
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Available Feb 4, Pre-Market

You May Also Like

More MRK News

MarketWatchNov 23

Merck to pay $425 million upfront to buy COVID-19 treatment developer OncoImmune

Shares of Merck & Co. Inc. MRK, +0.07% surged 3.1% in premarket trading Monday, after the drug maker announced a deal to buy clinical-stage biopharmaceutical co
ReutersNov 23

Merck adds experimental COVID-19 therapy with OncoImmune deal

FILE PHOTO: A man wearing a protective face mask walks past an illustration of a virus outside a regional science centre in Oldham, Britain August 3, 2020. REUT
MarketWatchNov 22

These 5 stocks will profit from the dollar's continuing decline

Things look mighty bleak for the dollar given the damage to the U.S. economy from the world’s worst coronavirus outbreak and our national debt that is soaring t
ReutersNov 20

Judge rebuffs Merck's renewed bid to arbitrate vaccine antitrust cases

A lawsuit accusing Merck & Co Inc of illegally stifling competition for its rotavirus vaccine RotaTeq can proceed as a class action, a Philadelphia federal judg